Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main Page
My Profile
My Assessments
My Life Story
Med Classes
Problems
Recent changes
Pharmacopedia
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Drilldown: Medicines
English
Tools
Tools
move to sidebar
hide
Actions
General
Printable version
Appearance
move to sidebar
hide
Choose a table:
Medicines (732)
Medicines
> uses:
'"`UNIQ--vote-000002C1-QINU`"'
&
starting dose:
100 mg at bedtime daily
&
fda max:
100 mg/d
Use the filters below to narrow your results.
generic:
Flibanserin (1)
brand:
Addyi (1)
classes:
Multimodal serotonergic; HSDD treatment (1)
mechanism:
5-HT1A agonist, 5-HT2A antagonist, with weaker activity at D4 and other receptors. Net effect involves enhanced prefrontal dopaminergic/noradrenergic tone with decreased serotonergic inhibition of sexual desire. (1)
uses:
(Click arrow to add another value)
None
·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"'
·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"'
·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"'
·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"'
·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"'
·
'"`UNIQ--vote-00000006-QINU`"'
·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"'
·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"'
·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"'
·
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"'
·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"'
·
Preventive treatment of migraine in adults (episodic and chronic)
·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"'
·
(investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"'
·
Acute treatment of migraine with or without aura in adults
·
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult)
·
ADHD, narcolepsy
·
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD.
·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024
Other values:
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023
Antimanic, Antidepressive, Antisuicide
Chronic migraine (≥15 headache days/month), cervical dystonia, blepharospasm, hyperhidrosis, overactive bladder, urinary incontinence, strabismus, spasticity, cosmetic problems
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA)
Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019)
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression.
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease.
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019)
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022)
Investigational for major depressive disorder; trials underway (phase 3 mixed results)
Major depressive disorder in adults (FDA-approved 2011)
Major depressive disorder in adults (FDA-approved 2013). Notable for evidence of cognitive benefit (processing speed) that distinguishes it from other antidepressants.
Major depressive disorder in adults (FDA-approved August 2022)
Mild to moderate pain; cough suppression (low-dose).
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
Pain, cough, disquiet
Postpartum depression (PPD) in adults
Postpartum depression (PPD) in adults (FDA-approved 2023)
Preventive treatment of migraine in adults
Preventive treatment of migraine in adults; episodic cluster headache
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022).
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline).
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021).
Schizophrenia, acute psychosis, agitation, delirium, Tourette syndrome, severe nausea
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020).
[[Type 2 diabetes mellitus]] (adjunct, second-line)
[[Type 2 diabetes mellitus]] (incl. pediatric ≥10 y) · [[Obesity]] (incl. pediatric ≥12 y) · [[Cardiovascular risk reduction]] in T2DM
[[Type 2 diabetes mellitus]] · [[Cardiovascular risk reduction]] in T2DM
[[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM
[[Type 2 diabetes mellitus]] · [[Obesity]] · [[Obstructive sleep apnea]] in obesity
'"`UNIQ--vote-0000000C-QINU`"', '"`UNIQ--vote-0000000D-QINU`"', '"`UNIQ--vote-0000000E-QINU`"', '"`UNIQ--vote-0000000F-QINU`"'
'"`UNIQ--vote-00000011-QINU`"'
'"`UNIQ--vote-00000013-QINU`"'
'"`UNIQ--vote-00000017-QINU`"'
'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"'
'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"'
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"'
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"'
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"'
'"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"'
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"'
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"'
'"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"'
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"'
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"'
'"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"', '"`UNIQ--vote-00000029-QINU`"', '"`UNIQ--vote-0000002A-QINU`"'
'"`UNIQ--vote-00000033-QINU`"', '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"'
'"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"'
'"`UNIQ--vote-00000039-QINU`"', '"`UNIQ--vote-0000003A-QINU`"', '"`UNIQ--vote-0000003B-QINU`"', '"`UNIQ--vote-0000003C-QINU`"', '"`UNIQ--vote-0000003D-QINU`"'
'"`UNIQ--vote-00000040-QINU`"'
'"`UNIQ--vote-00000042-QINU`"', '"`UNIQ--vote-00000043-QINU`"', '"`UNIQ--vote-00000044-QINU`"'
'"`UNIQ--vote-00000050-QINU`"'
'"`UNIQ--vote-00000055-QINU`"', '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"', '"`UNIQ--vote-00000058-QINU`"'
'"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"'
'"`UNIQ--vote-00000063-QINU`"', '"`UNIQ--vote-00000064-QINU`"'
'"`UNIQ--vote-00000065-QINU`"'
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"'
'"`UNIQ--vote-00000075-QINU`"', '"`UNIQ--vote-00000076-QINU`"', '"`UNIQ--vote-00000077-QINU`"'
'"`UNIQ--vote-00000088-QINU`"', '"`UNIQ--vote-00000089-QINU`"', '"`UNIQ--vote-0000008A-QINU`"', '"`UNIQ--vote-0000008B-QINU`"'
'"`UNIQ--vote-0000008F-QINU`"', '"`UNIQ--vote-00000090-QINU`"', '"`UNIQ--vote-00000091-QINU`"', '"`UNIQ--vote-00000092-QINU`"'
'"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"'
'"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"', '"`UNIQ--vote-00000097-QINU`"', '"`UNIQ--vote-00000098-QINU`"'
'"`UNIQ--vote-000000AD-QINU`"', '"`UNIQ--vote-000000AE-QINU`"'
'"`UNIQ--vote-000000B8-QINU`"', '"`UNIQ--vote-000000B9-QINU`"', '"`UNIQ--vote-000000BA-QINU`"', '"`UNIQ--vote-000000BB-QINU`"'
'"`UNIQ--vote-000000CF-QINU`"', '"`UNIQ--vote-000000D0-QINU`"', '"`UNIQ--vote-000000D1-QINU`"'
'"`UNIQ--vote-000000DA-QINU`"', '"`UNIQ--vote-000000DB-QINU`"', '"`UNIQ--vote-000000DC-QINU`"', '"`UNIQ--vote-000000DD-QINU`"'
'"`UNIQ--vote-000000F9-QINU`"', '"`UNIQ--vote-000000FA-QINU`"', '"`UNIQ--vote-000000FB-QINU`"'
'"`UNIQ--vote-00000119-QINU`"', '"`UNIQ--vote-0000011A-QINU`"', '"`UNIQ--vote-0000011B-QINU`"', '"`UNIQ--vote-0000011C-QINU`"'
'"`UNIQ--vote-0000013A-QINU`"', '"`UNIQ--vote-0000013B-QINU`"', '"`UNIQ--vote-0000013C-QINU`"', '"`UNIQ--vote-0000013D-QINU`"'
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"'
'"`UNIQ--vote-0000015B-QINU`"', '"`UNIQ--vote-0000015C-QINU`"', '"`UNIQ--vote-0000015D-QINU`"'
'"`UNIQ--vote-00000178-QINU`"', '"`UNIQ--vote-00000179-QINU`"'
'"`UNIQ--vote-0000019B-QINU`"', '"`UNIQ--vote-0000019C-QINU`"', '"`UNIQ--vote-0000019D-QINU`"', '"`UNIQ--vote-0000019E-QINU`"', '"`UNIQ--vote-0000019F-QINU`"', '"`UNIQ--vote-000001A0-QINU`"'
'"`UNIQ--vote-000001BA-QINU`"', '"`UNIQ--vote-000001BB-QINU`"'
'"`UNIQ--vote-000001D9-QINU`"', '"`UNIQ--vote-000001DA-QINU`"', '"`UNIQ--vote-000001DB-QINU`"', '"`UNIQ--vote-000001DC-QINU`"'
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"'
'"`UNIQ--vote-0000021C-QINU`"', '"`UNIQ--vote-0000021D-QINU`"', '"`UNIQ--vote-0000021E-QINU`"', '"`UNIQ--vote-0000021F-QINU`"', '"`UNIQ--vote-00000220-QINU`"', '"`UNIQ--vote-00000221-QINU`"'
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"'
'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"'
'"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"'
'"`UNIQ--vote-0000029D-QINU`"', '"`UNIQ--vote-0000029E-QINU`"', '"`UNIQ--vote-0000029F-QINU`"', '"`UNIQ--vote-000002A0-QINU`"', '"`UNIQ--vote-000002A1-QINU`"', '"`UNIQ--vote-000002A2-QINU`"'
'"`UNIQ--vote-000002C0-QINU`"', '"`UNIQ--vote-000002C1-QINU`"', '"`UNIQ--vote-000002C2-QINU`"', '"`UNIQ--vote-000002C3-QINU`"'
'"`UNIQ--vote-000002C1-QINU`"'
'"`UNIQ--vote-000002D8-QINU`"'
'"`UNIQ--vote-000002EE-QINU`"', '"`UNIQ--vote-000002EF-QINU`"'
'"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"'
'"`UNIQ--vote-0000032C-QINU`"', '"`UNIQ--vote-0000032D-QINU`"', '"`UNIQ--vote-0000032E-QINU`"', '"`UNIQ--vote-0000032F-QINU`"'
'"`UNIQ--vote-0000034F-QINU`"', '"`UNIQ--vote-00000350-QINU`"', '"`UNIQ--vote-00000351-QINU`"', '"`UNIQ--vote-00000352-QINU`"', '"`UNIQ--vote-00000353-QINU`"'
'"`UNIQ--vote-00000374-QINU`"', '"`UNIQ--vote-00000375-QINU`"', '"`UNIQ--vote-00000376-QINU`"', '"`UNIQ--vote-00000377-QINU`"'
'"`UNIQ--vote-00000393-QINU`"', '"`UNIQ--vote-00000394-QINU`"', '"`UNIQ--vote-00000395-QINU`"'
'"`UNIQ--vote-000003A0-QINU`"', '"`UNIQ--vote-000003A1-QINU`"'
'"`UNIQ--vote-000003B5-QINU`"', '"`UNIQ--vote-000003B6-QINU`"', '"`UNIQ--vote-000003B7-QINU`"', '"`UNIQ--vote-000003B8-QINU`"', '"`UNIQ--vote-000003B9-QINU`"'
'"`UNIQ--vote-000003D3-QINU`"', '"`UNIQ--vote-000003D4-QINU`"'
'"`UNIQ--vote-000003F6-QINU`"', '"`UNIQ--vote-000003F7-QINU`"', '"`UNIQ--vote-000003F8-QINU`"', '"`UNIQ--vote-000003F9-QINU`"', '"`UNIQ--vote-000003FA-QINU`"', '"`UNIQ--vote-000003FB-QINU`"'
'"`UNIQ--vote-00000415-QINU`"', '"`UNIQ--vote-00000416-QINU`"'
'"`UNIQ--vote-0000042D-QINU`"', '"`UNIQ--vote-0000042E-QINU`"', '"`UNIQ--vote-0000042F-QINU`"', '"`UNIQ--vote-00000430-QINU`"'
'"`UNIQ--vote-0000044C-QINU`"', '"`UNIQ--vote-0000044D-QINU`"', '"`UNIQ--vote-0000044E-QINU`"', '"`UNIQ--vote-0000044F-QINU`"'
'"`UNIQ--vote-00000468-QINU`"'
'"`UNIQ--vote-00000475-QINU`"', '"`UNIQ--vote-00000476-QINU`"', '"`UNIQ--vote-00000477-QINU`"', '"`UNIQ--vote-00000478-QINU`"', '"`UNIQ--vote-00000479-QINU`"', '"`UNIQ--vote-0000047A-QINU`"', '"`UNIQ--vote-0000047B-QINU`"', '"`UNIQ--vote-0000047C-QINU`"'
'"`UNIQ--vote-00000491-QINU`"'
'"`UNIQ--vote-000004AB-QINU`"', '"`UNIQ--vote-000004AC-QINU`"'
'"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"'
'"`UNIQ--vote-000004CA-QINU`"', '"`UNIQ--vote-000004CB-QINU`"', '"`UNIQ--vote-000004CC-QINU`"'
'"`UNIQ--vote-000004ED-QINU`"', '"`UNIQ--vote-000004EE-QINU`"', '"`UNIQ--vote-000004EF-QINU`"', '"`UNIQ--vote-000004F0-QINU`"', '"`UNIQ--vote-000004F1-QINU`"'
'"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"'
'"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"'
'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"'
'"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"'
'"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"'
'"`UNIQ--vote-0000056B-QINU`"'
'"`UNIQ--vote-00000586-QINU`"', '"`UNIQ--vote-00000587-QINU`"', '"`UNIQ--vote-00000588-QINU`"'
'"`UNIQ--vote-0000059A-QINU`"', '"`UNIQ--vote-0000059B-QINU`"'
'"`UNIQ--vote-0000059D-QINU`"'
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"'
'"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"'
'"`UNIQ--vote-000005D2-QINU`"', '"`UNIQ--vote-000005D3-QINU`"', '"`UNIQ--vote-000005D4-QINU`"', '"`UNIQ--vote-000005D5-QINU`"'
'"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"'
'"`UNIQ--vote-000005EF-QINU`"', '"`UNIQ--vote-000005F0-QINU`"', '"`UNIQ--vote-000005F1-QINU`"'
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"'
'"`UNIQ--vote-0000061F-QINU`"', '"`UNIQ--vote-00000620-QINU`"'
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"'
'"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"'
'"`UNIQ--vote-00000661-QINU`"', '"`UNIQ--vote-00000662-QINU`"', '"`UNIQ--vote-00000663-QINU`"', '"`UNIQ--vote-00000664-QINU`"', '"`UNIQ--vote-00000665-QINU`"'
'"`UNIQ--vote-00000669-QINU`"'
'"`UNIQ--vote-00000683-QINU`"', '"`UNIQ--vote-00000684-QINU`"', '"`UNIQ--vote-00000685-QINU`"', '"`UNIQ--vote-00000686-QINU`"'
'"`UNIQ--vote-0000069B-QINU`"', '"`UNIQ--vote-0000069C-QINU`"'
'"`UNIQ--vote-000006A2-QINU`"', '"`UNIQ--vote-000006A3-QINU`"', '"`UNIQ--vote-000006A4-QINU`"'
'"`UNIQ--vote-000006C0-QINU`"', '"`UNIQ--vote-000006C1-QINU`"', '"`UNIQ--vote-000006C2-QINU`"'
'"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"'
'"`UNIQ--vote-00000700-QINU`"', '"`UNIQ--vote-00000701-QINU`"', '"`UNIQ--vote-00000702-QINU`"', '"`UNIQ--vote-00000703-QINU`"', '"`UNIQ--vote-00000704-QINU`"'
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"'
'"`UNIQ--vote-00000717-QINU`"', '"`UNIQ--vote-00000718-QINU`"', '"`UNIQ--vote-00000719-QINU`"'
'"`UNIQ--vote-00000722-QINU`"', '"`UNIQ--vote-00000723-QINU`"', '"`UNIQ--vote-00000724-QINU`"', '"`UNIQ--vote-00000725-QINU`"'
'"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"'
'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"'
'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"', '"`UNIQ--vote-00000749-QINU`"', '"`UNIQ--vote-0000074A-QINU`"', '"`UNIQ--vote-0000074B-QINU`"', '"`UNIQ--vote-0000074C-QINU`"'
'"`UNIQ--vote-00000758-QINU`"', '"`UNIQ--vote-00000759-QINU`"', '"`UNIQ--vote-0000075A-QINU`"'
'"`UNIQ--vote-00000764-QINU`"'
'"`UNIQ--vote-00000780-QINU`"', '"`UNIQ--vote-00000781-QINU`"', '"`UNIQ--vote-00000782-QINU`"'
'"`UNIQ--vote-0000079C-QINU`"', '"`UNIQ--vote-0000079D-QINU`"'
'"`UNIQ--vote-000007C1-QINU`"', '"`UNIQ--vote-000007C2-QINU`"', '"`UNIQ--vote-000007C3-QINU`"', '"`UNIQ--vote-000007C4-QINU`"', '"`UNIQ--vote-000007C5-QINU`"', '"`UNIQ--vote-000007C6-QINU`"', '"`UNIQ--vote-000007C7-QINU`"'
'"`UNIQ--vote-000007E7-QINU`"', '"`UNIQ--vote-000007E8-QINU`"', '"`UNIQ--vote-000007E9-QINU`"', '"`UNIQ--vote-000007EA-QINU`"', '"`UNIQ--vote-000007EB-QINU`"'
'"`UNIQ--vote-00000805-QINU`"', '"`UNIQ--vote-00000806-QINU`"'
'"`UNIQ--vote-0000081E-QINU`"'
'"`UNIQ--vote-00000822-QINU`"', '"`UNIQ--vote-00000823-QINU`"'
'"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"'
'"`UNIQ--vote-00000862-QINU`"', '"`UNIQ--vote-00000863-QINU`"', '"`UNIQ--vote-00000864-QINU`"', '"`UNIQ--vote-00000865-QINU`"', '"`UNIQ--vote-00000866-QINU`"'
'"`UNIQ--vote-00000884-QINU`"', '"`UNIQ--vote-00000885-QINU`"', '"`UNIQ--vote-00000886-QINU`"', '"`UNIQ--vote-00000887-QINU`"'
'"`UNIQ--vote-000008A1-QINU`"', '"`UNIQ--vote-000008A2-QINU`"'
'"`UNIQ--vote-000008C0-QINU`"', '"`UNIQ--vote-000008C1-QINU`"', '"`UNIQ--vote-000008C2-QINU`"', '"`UNIQ--vote-000008C3-QINU`"'
'"`UNIQ--vote-000008E3-QINU`"', '"`UNIQ--vote-000008E4-QINU`"', '"`UNIQ--vote-000008E5-QINU`"', '"`UNIQ--vote-000008E6-QINU`"', '"`UNIQ--vote-000008E7-QINU`"'
'"`UNIQ--vote-00000909-QINU`"', '"`UNIQ--vote-0000090A-QINU`"', '"`UNIQ--vote-0000090B-QINU`"', '"`UNIQ--vote-0000090C-QINU`"', '"`UNIQ--vote-0000090D-QINU`"', '"`UNIQ--vote-0000090E-QINU`"'
'"`UNIQ--vote-00000932-QINU`"', '"`UNIQ--vote-00000933-QINU`"', '"`UNIQ--vote-00000934-QINU`"', '"`UNIQ--vote-00000935-QINU`"', '"`UNIQ--vote-00000936-QINU`"', '"`UNIQ--vote-00000937-QINU`"'
'"`UNIQ--vote-00000952-QINU`"', '"`UNIQ--vote-00000953-QINU`"'
'"`UNIQ--vote-00000977-QINU`"', '"`UNIQ--vote-00000978-QINU`"', '"`UNIQ--vote-00000979-QINU`"', '"`UNIQ--vote-0000097A-QINU`"', '"`UNIQ--vote-0000097B-QINU`"'
'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"'
'"`UNIQ--vote-000009BE-QINU`"', '"`UNIQ--vote-000009BF-QINU`"'
'"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"'
'"`UNIQ--vote-000009FF-QINU`"', '"`UNIQ--vote-00000A00-QINU`"', '"`UNIQ--vote-00000A01-QINU`"'
'"`UNIQ--vote-00000A1F-QINU`"', '"`UNIQ--vote-00000A20-QINU`"', '"`UNIQ--vote-00000A21-QINU`"'
'"`UNIQ--vote-00000A42-QINU`"', '"`UNIQ--vote-00000A43-QINU`"', '"`UNIQ--vote-00000A44-QINU`"', '"`UNIQ--vote-00000A45-QINU`"', '"`UNIQ--vote-00000A46-QINU`"'
'"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"'
'"`UNIQ--vote-00000A8C-QINU`"', '"`UNIQ--vote-00000A8D-QINU`"', '"`UNIQ--vote-00000A8E-QINU`"', '"`UNIQ--vote-00000A8F-QINU`"', '"`UNIQ--vote-00000A90-QINU`"'
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"'
'"`UNIQ--vote-00000ACD-QINU`"', '"`UNIQ--vote-00000ACE-QINU`"', '"`UNIQ--vote-00000ACF-QINU`"', '"`UNIQ--vote-00000AD0-QINU`"'
'"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"'
'"`UNIQ--vote-00000B08-QINU`"', '"`UNIQ--vote-00000B09-QINU`"'
'"`UNIQ--vote-00000B23-QINU`"', '"`UNIQ--vote-00000B24-QINU`"'
'"`UNIQ--vote-00000B42-QINU`"', '"`UNIQ--vote-00000B43-QINU`"', '"`UNIQ--vote-00000B44-QINU`"', '"`UNIQ--vote-00000B45-QINU`"'
'"`UNIQ--vote-00000B61-QINU`"', '"`UNIQ--vote-00000B62-QINU`"', '"`UNIQ--vote-00000B63-QINU`"'
'"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"'
'"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"'
'"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"'
'"`UNIQ--vote-00000BE3-QINU`"', '"`UNIQ--vote-00000BE4-QINU`"', '"`UNIQ--vote-00000BE5-QINU`"', '"`UNIQ--vote-00000BE6-QINU`"', '"`UNIQ--vote-00000BE7-QINU`"', '"`UNIQ--vote-00000BE8-QINU`"', '"`UNIQ--vote-00000BE9-QINU`"', '"`UNIQ--vote-00000BEA-QINU`"'
'"`UNIQ--vote-00000C0A-QINU`"', '"`UNIQ--vote-00000C0B-QINU`"', '"`UNIQ--vote-00000C0C-QINU`"', '"`UNIQ--vote-00000C0D-QINU`"', '"`UNIQ--vote-00000C0E-QINU`"'
'"`UNIQ--vote-00000C2E-QINU`"', '"`UNIQ--vote-00000C2F-QINU`"', '"`UNIQ--vote-00000C30-QINU`"', '"`UNIQ--vote-00000C31-QINU`"'
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"'
'"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"'
'"`UNIQ--vote-00000C8F-QINU`"', '"`UNIQ--vote-00000C90-QINU`"', '"`UNIQ--vote-00000C91-QINU`"'
'"`UNIQ--vote-00000CB0-QINU`"', '"`UNIQ--vote-00000CB1-QINU`"', '"`UNIQ--vote-00000CB2-QINU`"'
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"'
'"`UNIQ--vote-00000CEF-QINU`"', '"`UNIQ--vote-00000CF0-QINU`"', '"`UNIQ--vote-00000CF1-QINU`"', '"`UNIQ--vote-00000CF2-QINU`"', '"`UNIQ--vote-00000CF3-QINU`"', '"`UNIQ--vote-00000CF4-QINU`"'
'"`UNIQ--vote-00000D13-QINU`"', '"`UNIQ--vote-00000D14-QINU`"', '"`UNIQ--vote-00000D15-QINU`"', '"`UNIQ--vote-00000D16-QINU`"'
'"`UNIQ--vote-00000D38-QINU`"', '"`UNIQ--vote-00000D39-QINU`"', '"`UNIQ--vote-00000D3A-QINU`"', '"`UNIQ--vote-00000D3B-QINU`"', '"`UNIQ--vote-00000D3C-QINU`"', '"`UNIQ--vote-00000D3D-QINU`"'
'"`UNIQ--vote-00000D57-QINU`"', '"`UNIQ--vote-00000D58-QINU`"'
'"`UNIQ--vote-00000D7C-QINU`"', '"`UNIQ--vote-00000D7D-QINU`"', '"`UNIQ--vote-00000D7E-QINU`"', '"`UNIQ--vote-00000D7F-QINU`"', '"`UNIQ--vote-00000D80-QINU`"', '"`UNIQ--vote-00000D81-QINU`"'
'"`UNIQ--vote-00000D9E-QINU`"', '"`UNIQ--vote-00000D9F-QINU`"', '"`UNIQ--vote-00000DA0-QINU`"'
'"`UNIQ--vote-00000DBE-QINU`"', '"`UNIQ--vote-00000DBF-QINU`"', '"`UNIQ--vote-00000DC0-QINU`"', '"`UNIQ--vote-00000DC1-QINU`"'
'"`UNIQ--vote-00000DDF-QINU`"', '"`UNIQ--vote-00000DE0-QINU`"', '"`UNIQ--vote-00000DE1-QINU`"', '"`UNIQ--vote-00000DE2-QINU`"'
'"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"'
'"`UNIQ--vote-00000E23-QINU`"', '"`UNIQ--vote-00000E24-QINU`"', '"`UNIQ--vote-00000E25-QINU`"', '"`UNIQ--vote-00000E26-QINU`"', '"`UNIQ--vote-00000E27-QINU`"', '"`UNIQ--vote-00000E28-QINU`"', '"`UNIQ--vote-00000E29-QINU`"', '"`UNIQ--vote-00000E2A-QINU`"'
'"`UNIQ--vote-00000E4C-QINU`"', '"`UNIQ--vote-00000E4D-QINU`"', '"`UNIQ--vote-00000E4E-QINU`"', '"`UNIQ--vote-00000E4F-QINU`"', '"`UNIQ--vote-00000E50-QINU`"', '"`UNIQ--vote-00000E51-QINU`"'
'"`UNIQ--vote-00000E71-QINU`"', '"`UNIQ--vote-00000E72-QINU`"', '"`UNIQ--vote-00000E73-QINU`"', '"`UNIQ--vote-00000E74-QINU`"', '"`UNIQ--vote-00000E75-QINU`"'
'"`UNIQ--vote-00000E91-QINU`"', '"`UNIQ--vote-00000E92-QINU`"', '"`UNIQ--vote-00000E93-QINU`"'
'"`UNIQ--vote-00000EAF-QINU`"', '"`UNIQ--vote-00000EB0-QINU`"', '"`UNIQ--vote-00000EB1-QINU`"'
'"`UNIQ--vote-00000ECF-QINU`"', '"`UNIQ--vote-00000ED0-QINU`"', '"`UNIQ--vote-00000ED1-QINU`"', '"`UNIQ--vote-00000ED2-QINU`"'
'"`UNIQ--vote-00000EF4-QINU`"', '"`UNIQ--vote-00000EF5-QINU`"', '"`UNIQ--vote-00000EF6-QINU`"', '"`UNIQ--vote-00000EF7-QINU`"', '"`UNIQ--vote-00000EF8-QINU`"'
'"`UNIQ--vote-00000F1B-QINU`"', '"`UNIQ--vote-00000F1C-QINU`"', '"`UNIQ--vote-00000F1D-QINU`"', '"`UNIQ--vote-00000F1E-QINU`"', '"`UNIQ--vote-00000F1F-QINU`"'
'"`UNIQ--vote-00000F40-QINU`"', '"`UNIQ--vote-00000F41-QINU`"', '"`UNIQ--vote-00000F42-QINU`"', '"`UNIQ--vote-00000F43-QINU`"', '"`UNIQ--vote-00000F44-QINU`"'
'"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"'
'"`UNIQ--vote-00000F78-QINU`"', '"`UNIQ--vote-00000F79-QINU`"', '"`UNIQ--vote-00000F7A-QINU`"'
'"`UNIQ--vote-00000F98-QINU`"', '"`UNIQ--vote-00000F99-QINU`"', '"`UNIQ--vote-00000F9A-QINU`"', '"`UNIQ--vote-00000F9B-QINU`"'
'"`UNIQ--vote-00000FB3-QINU`"', '''adjunctive only''' (does not treat the underlying infection)
'"`UNIQ--vote-00000FCF-QINU`"', '"`UNIQ--vote-00000FD0-QINU`"', '"`UNIQ--vote-00000FD1-QINU`"'
'"`UNIQ--vote-00000FF3-QINU`"', '"`UNIQ--vote-00000FF4-QINU`"', '"`UNIQ--vote-00000FF5-QINU`"', '"`UNIQ--vote-00000FF6-QINU`"', '"`UNIQ--vote-00000FF7-QINU`"', '"`UNIQ--vote-00000FF8-QINU`"'
'"`UNIQ--vote-00001016-QINU`"', '"`UNIQ--vote-00001017-QINU`"', '"`UNIQ--vote-00001018-QINU`"', '"`UNIQ--vote-00001019-QINU`"'
'"`UNIQ--vote-00001035-QINU`"', '"`UNIQ--vote-00001036-QINU`"', '"`UNIQ--vote-00001037-QINU`"'
'"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"'
'"`UNIQ--vote-00001069-QINU`"', '"`UNIQ--vote-0000106A-QINU`"'
'"`UNIQ--vote-0000108C-QINU`"', '"`UNIQ--vote-0000108D-QINU`"', '"`UNIQ--vote-0000108E-QINU`"', '"`UNIQ--vote-0000108F-QINU`"', '"`UNIQ--vote-00001090-QINU`"', '"`UNIQ--vote-00001091-QINU`"'
'"`UNIQ--vote-000010AF-QINU`"', '"`UNIQ--vote-000010B0-QINU`"', '"`UNIQ--vote-000010B1-QINU`"', '"`UNIQ--vote-000010B2-QINU`"'
'"`UNIQ--vote-000010CE-QINU`"', '"`UNIQ--vote-000010CF-QINU`"', '"`UNIQ--vote-000010D0-QINU`"'
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"'
'"`UNIQ--vote-0000113C-QINU`"', '"`UNIQ--vote-0000113D-QINU`"', '"`UNIQ--vote-0000113E-QINU`"'
'"`UNIQ--vote-0000115F-QINU`"', '"`UNIQ--vote-00001160-QINU`"', '"`UNIQ--vote-00001161-QINU`"', '"`UNIQ--vote-00001162-QINU`"', '"`UNIQ--vote-00001163-QINU`"'
'"`UNIQ--vote-0000117B-QINU`"'
'"`UNIQ--vote-00001199-QINU`"', '"`UNIQ--vote-0000119A-QINU`"', '"`UNIQ--vote-0000119B-QINU`"'
'"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"'
'"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"'
'"`UNIQ--vote-000011F6-QINU`"', '"`UNIQ--vote-000011F7-QINU`"', '"`UNIQ--vote-000011F8-QINU`"'
'"`UNIQ--vote-00001215-QINU`"', '"`UNIQ--vote-00001216-QINU`"', '"`UNIQ--vote-00001217-QINU`"'
'"`UNIQ--vote-00001235-QINU`"', '"`UNIQ--vote-00001236-QINU`"', '"`UNIQ--vote-00001237-QINU`"', '"`UNIQ--vote-00001238-QINU`"'
'"`UNIQ--vote-0000124D-QINU`"', '"`UNIQ--vote-0000124E-QINU`"', '"`UNIQ--vote-0000124F-QINU`"'
'"`UNIQ--vote-0000126B-QINU`"', '"`UNIQ--vote-0000126C-QINU`"', '"`UNIQ--vote-0000126D-QINU`"'
'"`UNIQ--vote-00001286-QINU`"'
'"`UNIQ--vote-0000129E-QINU`"'
'"`UNIQ--vote-000012B7-QINU`"', '"`UNIQ--vote-000012B8-QINU`"', '"`UNIQ--vote-000012B9-QINU`"', '"`UNIQ--vote-000012BA-QINU`"', '"`UNIQ--vote-000012BB-QINU`"'
'"`UNIQ--vote-000012CE-QINU`"', '"`UNIQ--vote-000012CF-QINU`"', '"`UNIQ--vote-000012D0-QINU`"'
'"`UNIQ--vote-000012E5-QINU`"', '"`UNIQ--vote-000012E6-QINU`"', '"`UNIQ--vote-000012E7-QINU`"', '"`UNIQ--vote-000012E8-QINU`"'
'"`UNIQ--vote-00001303-QINU`"', '"`UNIQ--vote-00001304-QINU`"', '"`UNIQ--vote-00001305-QINU`"', '"`UNIQ--vote-00001306-QINU`"', '"`UNIQ--vote-00001307-QINU`"', '"`UNIQ--vote-00001308-QINU`"', '"`UNIQ--vote-00001309-QINU`"'
'"`UNIQ--vote-0000131A-QINU`"', '"`UNIQ--vote-0000131B-QINU`"'
'"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"'
'"`UNIQ--vote-00001341-QINU`"', '"`UNIQ--vote-00001342-QINU`"'
'"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"'
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"'
'"`UNIQ--vote-00001393-QINU`"', '"`UNIQ--vote-00001394-QINU`"', '"`UNIQ--vote-00001395-QINU`"', '"`UNIQ--vote-00001396-QINU`"', '"`UNIQ--vote-00001397-QINU`"'
'"`UNIQ--vote-000013B3-QINU`"', '"`UNIQ--vote-000013B4-QINU`"', '"`UNIQ--vote-000013B5-QINU`"'
'"`UNIQ--vote-000013CF-QINU`"', '"`UNIQ--vote-000013D0-QINU`"'
'"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"'
'"`UNIQ--vote-00001414-QINU`"', '"`UNIQ--vote-00001415-QINU`"', '"`UNIQ--vote-00001416-QINU`"', '"`UNIQ--vote-00001417-QINU`"', '"`UNIQ--vote-00001418-QINU`"'
'"`UNIQ--vote-0000143C-QINU`"', '"`UNIQ--vote-0000143D-QINU`"', '"`UNIQ--vote-0000143E-QINU`"', '"`UNIQ--vote-0000143F-QINU`"', '"`UNIQ--vote-00001440-QINU`"', '"`UNIQ--vote-00001441-QINU`"'
'"`UNIQ--vote-0000145E-QINU`"', '"`UNIQ--vote-0000145F-QINU`"', '"`UNIQ--vote-00001460-QINU`"'
'"`UNIQ--vote-0000147C-QINU`"', '"`UNIQ--vote-0000147D-QINU`"', '"`UNIQ--vote-0000147E-QINU`"'
'"`UNIQ--vote-0000149A-QINU`"', '"`UNIQ--vote-0000149B-QINU`"', '"`UNIQ--vote-0000149C-QINU`"'
'"`UNIQ--vote-000014BE-QINU`"', '"`UNIQ--vote-000014BF-QINU`"', '"`UNIQ--vote-000014C0-QINU`"', '"`UNIQ--vote-000014C1-QINU`"', '"`UNIQ--vote-000014C2-QINU`"'
'"`UNIQ--vote-000014DF-QINU`"', '"`UNIQ--vote-000014E0-QINU`"', '"`UNIQ--vote-000014E1-QINU`"'
'"`UNIQ--vote-000014F9-QINU`"'
'"`UNIQ--vote-00001515-QINU`"', '"`UNIQ--vote-00001516-QINU`"'
'"`UNIQ--vote-0000152F-QINU`"'
'"`UNIQ--vote-0000154B-QINU`"', '"`UNIQ--vote-0000154C-QINU`"'
'"`UNIQ--vote-00001567-QINU`"'
'"`UNIQ--vote-00001582-QINU`"'
'"`UNIQ--vote-0000159D-QINU`"', '"`UNIQ--vote-0000159E-QINU`"'
'"`UNIQ--vote-000015B6-QINU`"'
'"`UNIQ--vote-000015D0-QINU`"'
Search
starting dose:
(Click arrow to add another value)
None
·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose
·
'''5 mg PO at bedtime for women, 5-10 mg for men''' (per FDA's 2013 sex-specific dose reduction for women due to slower clearance). Ambien CR 6.25 mg women / 6.25-12.5 mg men. Intermezzo SL 1.75 mg women / 3.5 mg men
·
0.25 mg
·
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy
·
0.4 mg PO once daily, 30 minutes after the same meal each day
·
0.5 mg PO once daily
·
0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg
·
0.5-2 mg/kg/d divided or single morning dose for acute conditions; lowest effective dose for chronic conditions, with planned taper
·
0.5-3 mg PO 30-60 minutes before bedtime. Some patients respond to micro-doses (0.3 mg) without additional benefit at higher doses. For circadian phase shifting, timing relative to dim-light melatonin onset matters more than absolute dose
·
0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use
·
0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"'
·
1 capsule (20/10 mg dextromethorphan/quinidine) PO once daily × 7 days, then 1 capsule BID
·
1 drop in affected eye(s) TID (monotherapy); BID with timolol (Cosopt)
·
1 drop in the affected eye(s) once daily in the evening
·
1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime
·
1 g PO QID on an empty stomach (1 hour before meals and at bedtime); 1 g BID for maintenance
·
1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN)
·
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg
·
1 mg PO once daily
Other values:
1 tablet (4.8355 mg oxycodone / 325 mg aspirin) PO every 6 hours as needed
1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours
1 tablet (dextromethorphan 45 mg / bupropion 105 mg) PO daily × 3 days, then increase to 1 tablet BID
1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d
1-2 capsules (50 mg butalbital / 325 mg aspirin / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d
1-2 mg PO once daily with breakfast; titrate by glycemic response
1-2 tablets (15-60 mg codeine, 300-600 mg acetaminophen) PO every 4-6 hours as needed
1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks
10 mg
10 mg (one spray) intranasally in one nostril
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned)
10 mg PO once daily
10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg
10 mg PO once daily (5 mg in older adults or if sedation occurs)
10 mg PO once daily in the evening (adults); 4-5 mg in children
10 mg PO once daily in the morning; 5 mg starting in heart failure
10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food)
10 mg PO once daily, with or without food
10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed
10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed
10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID
10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH
10 mg ~1 h before sexual activity
10 mg/kg IV every 2 weeks
10-20 mEq PO daily for prevention; treat established hypokalemia per measured deficit, typically 40-100 mEq/d in divided doses; IV 10 mEq/h peripheral, 20 mEq/h central with telemetry
10-20 mg PO once daily
10-20 mg PO once daily (5 mg in Asian ancestry, elderly, hypothyroidism, or strong CYP/SLCO1B1 interactions)
10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk)
10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2)
10-40 mg PO daily depending on hyperthyroidism severity; titrate by clinical and biochemical response (target TSH/free T4)
100 mg IV every 3 months; may increase to 300 mg IV every 3 months
100 mg PO BID × 5 days (Macrobid) for cystitis; 50-100 mg HS for chronic prophylaxis
100 mg PO BID; rickettsial 200 mg/d; doxy-PEP 200 mg within 72 hours after condomless sex
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis)
100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease)
100 mg at bedtime daily
100 mg ~15 min before sexual activity
100-200 mg PO TID (max 600 mg/d)
100-200 mg PO TID after meals × no more than 2 days when used with concurrent antibiotic
100-200 mg PO once or twice daily; pediatric weight-based
1000 mg PO once daily; 500-2000 mg/d in single or divided doses
10–40 mg (situational anxiety); 40 mg BID (HTN)
12.5-25 mg PO once daily
12.5-25 mg PO once daily; titrate to 50 mg
140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume)
145 mcg PO once daily for chronic idiopathic constipation; 290 mcg daily for IBS-C; pediatric 72 mcg daily
15 mg PO at bedtime, titrate to 30-45 mg/day after 1-2 weeks. '''Counterintuitive dose paradox''': lower doses (7.5-15 mg) are more sedating than higher doses because H1 antihistamine effect dominates at low dose
15-30 mg PO once daily; titrate to 45 mg
15-37.5 mg PO once daily before breakfast or 1-2 hours after; Lomaira 8 mg TID
150 mg PO once daily; titrate to 300 mg if needed
18 mcg DPI once daily (HandiHaler); 2.5 mcg per actuation × 2 inhalations once daily (Respimat)
2 g PO BID with meals (4 g/d total)
2 mg PO every 6-8 hours; titrate by 2-4 mg per dose every 1-4 days; maximum single dose 16 mg, maximum daily dose 36 mg
2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days
2.25 g at bedtime + 2.25 g 2.5–4 h later; titrate weekly to 6–9 g/night total
2.5 mg IR, 5 mg XR, or 12.5mg Mydayis
2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d
2.5 mg SC weekly × 4 wk (non-therapeutic ramp)'"`UNIQ--ref-000002FB-QINU`"'
2.5-5 mg PO once daily; titrate to 10 mg/d
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration)
20 mg PO QID (start 10 mg and titrate); IM 20 mg q6h short-term
20 mg PO once daily 30-60 minutes before breakfast
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed
20 mg PO once daily; titrate to 40 mg/day after 1 week if tolerated. Elderly (>60) and hepatic impairment: 20 mg/day ceiling
20 mg PO twice daily, or 40 mg at bedtime
20-40 mg PO once daily, 30-60 minutes before breakfast
20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed
200-400 mg PO daily; '''dose by actual body weight ≤5 mg/kg/d''' to reduce retinopathy risk (AAO 2016 guideline)
200-400 mg PO every 4-6 hours as needed. OTC max 1200 mg/day without provider direction; prescription max 3200 mg/day divided
200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER)
225 mg SC monthly, or 675 mg SC every 3 months (quarterly)
25 mg
25 mg (schizophrenia, immediate-release); 50 mg (bipolar mania, immediate-release); 50 mg (Seroquel XR, schizophrenia or bipolar)
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate
25 mg PO once daily for HFrEF and primary aldosteronism; up to 100 mg/d for ascites; 50-200 mg/d for hirsutism
25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed
25-50 mg PO once daily; titrate to 100 mg/day
250-500 mg PO BID × 7-14 days; IV 1.5 g q8h for serious infections
250-500 mg PO QID; 7.5-12.5 mg/kg IV q6h; topical and ophthalmic per formulation
250-500 mg PO every 6-8 hours
25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF
30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d
300 mg PO at bedtime night 1, 300 mg BID day 2, 300 mg TID day 3; titrate to clinical effect, commonly 1800-3600 mg/day divided TID
325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden
325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours
34 mg PO once daily
4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake
4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID)
4 mg PO initially, then 2 mg after each loose stool, '''not to exceed 16 mg/d''' (8 mg OTC); chronic-use lower
4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions)
40 mg PO once daily; titrate to 80 mg
40 mg PO or IV once daily
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week
400 mg PO/IV once daily
42 mg PO once daily with food (no titration)
5 mg / 325 mg PO every 4-6 hours as needed; total acetaminophen <3 g/d
5 mg PO
5 mg PO TID or 7.5 mg PO BID; titrate by 5 mg every 2-3 days to clinical effect, commonly 30-60 mg/day divided BID-TID
5 mg PO at bedtime; may increase to 10 mg if inadequate
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin)
5 mg PO once daily at bedtime; titrate to 10 mg/day after 4-6 weeks. Severe Alzheimer disease: may escalate to 23 mg/day. Adlarity patch: 5 or 10 mg/day applied weekly
5 mg PO once daily in the evening
5 mg PO once daily, 30 minutes before breakfast; XL: 5 mg with breakfast
5 mg PO once daily; titrate by 5 mg weekly to target 10 mg PO BID. XR formulation: 7 mg/day, titrate to 28 mg/day
5 mg PO once daily; titrate to 10 mg after 2 weeks if needed
5 mg daily
5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours
5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF
5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion)
5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses
50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion
50 mg PO at bedtime; titrate by 50 mg every 4-7 days to clinical effect. Total daily doses >100 mg divided BID. Luvox CR: 100 mg PO once daily, may titrate to 300 mg/day
50 mg PO daily (25 mg in volume depletion or hepatic impairment)
50 mg PO once daily ('''no titration required''', distinguishing it favorably from venlafaxine)
50 mg PO once daily with fatty food in the evening × 14 days
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH)
500 mg PO TID or 875 mg PO BID for most indications; 80-90 mg/kg/d divided BID in pediatric otitis media
500 mg PO TID × 7-10 days (most indications); 2 g single dose for trichomoniasis; 500 mg IV q8h for severe anaerobic infection; rectal 1 g BID
500 mg PO day 1, then 250 mg PO daily days 2-5 (Z-Pak); 1 g PO single dose for chlamydia; pediatric dosing 10 mg/kg day 1, 5 mg/kg days 2-5
500 mg PO every 6 hours, or 250 mg every 6 hours for mild infections
500 mg PO once or twice daily with meals; titrate weekly to limit GI effects
500-750 mg PO BID; 400 mg IV q8-12h
500-750 mg PO/IV once daily
6/25 mg PO once daily in the evening; titrate within range 3/25 to 18/75 mg by clinical response and tolerability
60 mg PO BID or 180 mg PO once daily
7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg
70 mg SC monthly; may increase to 140 mg monthly
700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance
75 mg PO once daily for maintenance; 300-600 mg PO loading dose in ACS or before PCI
80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID)
A ''marduuf'' bundle (~50 g fresh leaves) chewed over a couple of hours
A measured pour of absinthe diluted 5:1 with cold water over sugar (the louche ritual)
ACS/PCI: 180 mg PO loading dose, then 90 mg PO BID for 12 months; long-term post-MI: 60 mg BID
ADHD (Kapvay ER): 0.1 mg PO at bedtime, titrate weekly to 0.4 mg/day divided BID. HTN (IR): 0.1 mg PO BID, titrate by 0.1 mg increments
ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day
Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis
Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction
Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses
Acute migraine: 75 mg PO at onset, maximum one dose per 24 hours. Preventive: 75 mg PO every other day
Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID
Adult: 15–60 mg every 4 hours as needed.
Adult: 500 mg PO BID, titrate by 1000 mg/day every 2 weeks. Pediatric: 10-20 mg/kg/day divided BID, weight-titrated
Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated'''
Allergy: 25-50 mg PO every 4-6 hours. Insomnia: 25-50 mg PO at bedtime. IV (acute dystonia, severe allergic reaction): 25-50 mg slow IV push
Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID
Anaphylaxis IM 0.3-0.5 mg (adult) into lateral thigh, repeat q5-15 minutes prn; pediatric 0.01 mg/kg IM (max 0.3 mg, max 0.5 mg in adolescents); cardiac arrest 1 mg IV/IO q3-5 minutes; severe asthma neb 0.1 mg/kg up to 5 mg; never IV bolus for anaphylaxis outside critical care
Antenatal: Celestone Soluspan 12 mg IM q24h × 2 doses; topical: pea-sized amount BID; intra-articular varies by joint
Antiplatelet: 81 mg PO once daily. Acute MI/stroke: 162-325 mg chewed. Analgesic: 325-650 mg PO every 4-6 hours as needed
Anxiety: 0.25 mg PO BID, titrate by 0.125-0.25 mg every 3 days to target 1-4 mg/day divided. Seizures: 1.5 mg/day divided TID, titrate by 0.5-1 mg every 3 days
Anxiety: 0.5-1 mg PO BID-TID. Insomnia: 1-2 mg PO at bedtime. Status epilepticus: 4 mg IV (adult), repeat after 5-10 minutes if needed. Acute agitation: 1-2 mg IM
Anxiety: 2-10 mg PO 2-4 times daily. Alcohol withdrawal: 10-20 mg PO/IV every 4-6 hours, symptom-triggered. Status epilepticus: 5-10 mg IV. Breakthrough seizures: Diastat rectal 0.2-0.5 mg/kg or Valtoco intranasal 5-20 mg
Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided
Apply a thin film to affected area BID; '''limit to 2 weeks''' continuous use and ≤50 g/week (cream/ointment); ≤50 mL/week (foam/solution); avoid face, intertriginous areas
Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis
Byetta: 5 µg SC twice daily, within 60 min before morning and evening meals'"`UNIQ--ref-000000E3-QINU`"' · Bydureon BCise: 2 mg SC once weekly'"`UNIQ--ref-000000E4-QINU`"'
Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks
Chronic migraine (PREEMPT protocol): 155 units divided across 31 sites in 7 head/neck muscle groups every 12 weeks
Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day
Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure
Contraception: Depo-Provera 150 mg IM every 13 weeks; Depo-SubQ 104 mg SC every 12-13 weeks; oral cycling: 5-10 mg PO daily ×5-10 days for amenorrhea
Deficiency: 50,000 IU PO weekly for 8-12 weeks, then maintenance 800-2,000 IU/day; maintenance OTC dosing typically 800-2,000 IU/d
Depression (rarely used now): 25-75 mg PO at bedtime, titrate to 150 mg/day. Neuropathic pain / migraine prophylaxis: 10-25 mg at bedtime, titrate by 10-25 mg weekly to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions apply)
Depression: 25 mg PO TID-QID or 75 mg at bedtime, titrate to 75-150 mg/day. Neuropathic pain: 10-25 mg at bedtime, titrate to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions, though less than amitriptyline)
Depression: 25-75 mg/day to start, titrate to 75-150 mg/day at bedtime. Insomnia (Silenor): 3 mg PO 30 minutes before bedtime, max 6 mg. Topical (Prudoxin): apply to affected area every 3-4 hours
ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion
ER 30-60 mg PO once daily; immediate-release 10 mg PO TID (now rarely used for hypertension due to reflex tachycardia)
For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength
Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d.
General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported
HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily
Heart failure: 3.125 mg PO BID, doubling every 2 weeks as tolerated to target 25 mg BID (50 mg BID if >85 kg). Hypertension: 6.25 mg PO BID, titrate to 25 mg BID
Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading
ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID
IM: 60 mg single dose or 30 mg every 6 hours. IV: 30 mg every 6 hours. Oral (continuation only): 10-20 mg every 4-6 hours. Sprix nasal: 31.5 mg every 6-8 hours. '''Maximum 5 days total combined use'''
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily
IR 200-400 mg PO every 6-8 hours; ER 400-1000 mg PO once daily
IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC)
IR 5 mg PO TID; titrate to 10 mg TID if needed. Amrix ER 15 mg PO once daily. Off-label insomnia / fibromyalgia: 5-10 mg PO at bedtime
IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses
IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: '''10 mg PO every 12 hours (lowest available)'''; titrate slowly to clinical effect
IR oral 50 mg PO TID or 75 mg BID. Voltaren 1% gel: apply 2-4 g to affected area QID. Pennsaid 2%: 40 drops to knee BID. Flector patch: every 12 hours
IR oral: 15-30 mg every 4 hours as needed. ER opioid-naive: 15-30 mg every 12 hours. IV/IM/SC: 2-10 mg every 3-4 hours. Epidural / intrathecal: see surgical or palliative-care protocols
IR: 25-50 mg PO every 4-6 hours as needed, titrate as tolerated. ER: 100 mg PO once daily, titrate by 100 mg every 5 days
IR: 60 mg PO every 4-6 hours. 12-hour ER: 120 mg PO every 12 hours. 24-hour ER: 240 mg PO once daily. Pediatric: weight-based
IV: 1 mEq/kg bolus in arrest indication, then titrated to ABG and clinical status; PO: 325-2000 mg up to QID as antacid
IV: traditional 1-1.7 mg/kg q8h or extended-interval 5-7 mg/kg q24h with target-trough monitoring; inhaled CF 300 mg BID × 28 days on / 28 days off; ophthalmic 1-2 drops in affected eye(s) q4h
Indication-specific: 0.5-9 mg PO/IV daily for inflammation; 4 mg IV q6h for cerebral edema; 40 mg PO once weekly in MM; 6 mg PO/IV daily ×10 days for severe COVID-19; 0.6 mg/kg PO single dose for croup (max 16 mg)
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site.
Induction: 2/0.5 to 4/1 mg SL once in moderate withdrawal; titrate to 12–16/3–4 mg/d by day 2–3
Infiltration: 1-2% solution; '''4.5 mg/kg ceiling without epinephrine, 7 mg/kg with epinephrine'''. IV antiarrhythmic: 1-1.5 mg/kg bolus then infusion 1-4 mg/minute. Lidoderm patch: up to 3 patches per 12 hours
Inhaled (Flovent HFA) 88 mcg BID; intranasal (Flonase) 2 sprays/nostril daily; topical (Cutivate) 0.05% cream BID
Initial genital herpes 1 g PO BID × 10 days; recurrent 500 mg BID × 3 days; suppression 500 mg-1 g PO daily; zoster 1 g TID × 7 days
Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days
Insomnia (off-label): 25-50 mg PO at bedtime, titrate to effect. Depression: 150 mg/day divided BID-TID; titrate to 400 mg/day outpatient or 600 mg/day inpatient
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID
Intranasal Nasonex 2 sprays/nostril daily (50 mcg/spray); inhaled Asmanex 220 mcg DPI 1-2 inhalations daily/BID; topical Elocon 0.1% cream daily
Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response
Isosorbide mononitrate ER: 30-60 mg PO once daily in the morning, titrate to 120-240 mg/d; isosorbide dinitrate IR: 5-20 mg PO TID with a 12-14 hour nitrate-free interval to prevent tolerance
MDD/GAD: 20 mg PO once daily. Panic disorder: 10 mg titrating to 40 mg. OCD: 20 mg titrating to 40-60 mg. CR: 25 mg/day. Brisdelle: 7.5 mg at bedtime for hot flashes
MDI 90 mcg/puff, 2 puffs q4-6h prn; nebulized 2.5 mg in 3 mL saline q4-6h
Maintenance 800-2,000 IU PO daily; deficiency replacement 50,000 IU PO weekly for 8-12 weeks then maintenance, or equivalent daily dosing 5,000-10,000 IU/d
Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster.
Migraine: 25 mg PO at bedtime, titrate by 25 mg weekly to target 100 mg/day divided BID. Seizures: 25-50 mg/day, titrate weekly to 200-400 mg/day divided BID
Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support
Motion sickness: 25-50 mg PO 1 hour before travel, repeat every 24 hours as needed. Vertigo: 25-100 mg/day divided
NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate.
Nebulized 500 mcg q6-8h (or with albuterol as DuoNeb); MDI 17 mcg/puff, 2 puffs QID; nasal 0.03% or 0.06% spray BID-TID
Neuropathic pain: 75 mg PO BID, titrate to 150 mg BID after 1 week. Fibromyalgia: 75 mg PO BID, titrate to 150 mg BID. Anxiety (off-label): 75-150 mg/day divided BID-TID
Niaspan ER 500 mg PO at bedtime, titrate weekly to 1-2 g/d; flushing-protective aspirin 30-60 minutes before dose; pellagra replacement 100-500 mg/d
No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl).
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
OTC dentifrice/rinse 0.05-0.5% fluoride daily; Rx 1.1% sodium fluoride toothpaste/gel daily; supplements (where local water non-fluoridated) age-titrated 0.25-1 mg/d
OTC: 220 mg PO every 8-12 hours, max 660 mg/24h. Rx: 250-500 mg PO BID. Acute gout: 750 mg loading then 250 mg every 8 hours
One cup (~40–60 mg caffeine; about half of brewed coffee)
One cup (~80–145 mg caffeine for brewed; 60–100 mg for instant)
Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily
Ophthalmic 1 drop in each eye every 8-12 hours
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID
Ophthalmic: 1 drop 0.5% in affected eye(s) BID (or once daily for XE / Istalol). Oral hypertension: 10 mg PO BID, titrate to 60 mg/day. Migraine prophylaxis: 10 mg BID, titrate to 30 mg/day
Oral 0.25 mcg daily, titrate by serum calcium and PTH; IV in CKD 0.5-3 mcg three times weekly
Oral 1-2 mg daily; transdermal patch 0.025-0.05 mg/d twice weekly; transdermal gel 0.5-1 g/d; vaginal 10 mcg tablet twice weekly for GSM. Always combine with a progestogen in patients with an intact uterus.
Oral 200-400 mg BID; ophthalmic 1-2 drops in affected eye(s) q2-4h initially, then taper; otic 5-10 drops in affected ear BID
Oral 300-450 mg PO QID; IV 600-900 mg q8h; topical 1% solution/gel BID; vaginal 100 mg ovule × 3 days or 2% cream × 7 days
Oral load 800-1600 mg/d in divided doses for 1-3 weeks, then 600-800 mg/d for 1 month, then 200-400 mg/d maintenance; IV 150 mg over 10 min then 1 mg/min for 6 hours then 0.5 mg/min
Oral: 100 mg PO BID, titrate to 400 mg BID. IV: 20 mg over 2 minutes, repeat 40-80 mg every 10 minutes as needed (maximum cumulative 300 mg); continuous infusion 2 mg/minute
Oral: 1000-1500 mg elemental calcium/day in divided doses for supplementation; IV gluconate 1 g (4.65 mEq) over 5-10 min for hyperkalemia or symptomatic hypocalcemia
Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm
Oral: 250 mg PO once daily × 6 weeks (fingernails) or 12 weeks (toenails); topical: cream BID × 1-2 weeks
Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks
Oral: 5 mg PO TID, titrate by 5 mg per dose every 3 days. Intrathecal: bolus test dose, then continuous infusion via implanted pump
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours
Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours
Ozempic: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000245-QINU`"' · Wegovy: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000246-QINU`"' · Rybelsus: 3 mg PO daily × 30 d'"`UNIQ--ref-00000247-QINU`"'
PO 10 mg QID; IV 5-10 mg every 20-30 minutes for hypertensive emergency
PO Medrol Dosepak (5-day taper from 24 mg to 4 mg) is the prototypic short-course outpatient regimen; IV pulse 1 g daily for 3-5 days for MS relapse; intra-articular 4-80 mg per joint q1-5 weeks
POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d
Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed
Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed
Pediatric 1-2 mg/kg/d (max 60 mg) PO for asthma exacerbation; adult dosing similar to prednisone milligram-for-milligram (~1:1 potency)
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg.
Physiologic replacement 15-25 mg/d divided (e.g., 10 mg AM, 5 mg noon, 5 mg afternoon); stress dose 50-100 mg IV q6-8h; adrenal crisis 100 mg IV then 50-100 mg q6h; topical 0.5-2.5% applied 2-4×/d
Replacement oxide 400-800 mg/d in divided doses (high diarrhea rate); citrate 200-400 mg/d (better tolerated, better absorbed); IV sulfate 1-2 g over 5-60 minutes for hypomagnesemia or torsades; eclampsia 4-6 g IV loading then 1-2 g/h
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly
Replacement: 15-30 mg (22.5-45 IU) daily; NASH: 800 IU daily; AREDS-2: 400 IU daily (in combination formula)
Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose. Typical total daily dose 0.5-1 U/kg/d split between basal and prandial coverage in T1DM
SL 0.3-0.6 mg every 5 minutes up to 3 doses for acute angina (call EMS if not resolved after the third); IV infusion 5-10 mcg/min titrated; transdermal patch 0.2-0.4 mg/hr for 12-14 hours daily (nitrate-free interval prevents tolerance)
SR 150 mg PO once daily for 3 days, then 150 mg BID. XL 150 mg PO once daily for 4 days, then 300 mg once daily. Zyban (smoking cessation) 150 mg daily for 3 days, then 150 mg BID
Schizophrenia / acute mania: 5-10 mg PO once daily, target 10-15 mg/day. Acute agitation IM: 10 mg, may repeat in 2 hours. Relprevv LAI: 150-300 mg every 4 weeks after oral overlap
Schizophrenia / mania: 1 mg PO BID, titrate to 4-8 mg/day. Pediatric autism irritability: 0.25-0.5 mg/day, weight-titrated. Consta LAI: 25 mg IM every 2 weeks after oral overlap
Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily.
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg.
Seizures: 10-15 mg/kg/d divided BID-TID, titrate to therapeutic level (50-100 mcg/mL); bipolar mania: 750 mg/d divided, titrate
Seizures: 100-125 mg PO at bedtime x 3 days, then BID, then TID, escalating to 750-1500 mg/day. Essential tremor: 25-50 mg PO at bedtime, titrate slowly to 250-750 mg/day
Seizures: 200 mg PO BID, titrate by 200 mg/week to 800-1200 mg/day. Trigeminal neuralgia: 100-200 mg BID, titrate to 200-400 mg TID. Bipolar: 200 mg BID, titrate to 1600 mg/day
Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h
Strongyloides 200 mcg/kg PO single dose; scabies 200 mcg/kg PO repeated at 7-14 days; onchocerciasis 150 mcg/kg q6-12 months
Surgical scrub 4% CHG; preop skin prep 2% CHG/70% isopropyl alcohol (ChloraPrep); ICU bathing 2% CHG daily; oral rinse 0.12% 15 mL twice daily for 30 seconds
Topical 0.025-0.5% cream/ointment BID; intra-articular 5-40 mg per joint q3-6 months; intranasal Nasacort 110 mcg/spray, 2 sprays/nostril daily; oral paste 0.1% to lesion 2-3×/d
Topical 2% shampoo twice weekly for seborrheic dermatitis or tinea versicolor; oral use restricted by 2013 FDA action to indications where alternatives have failed
Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks
Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy
Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush
Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days
Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses
Transplant: 5-10 mg/kg/d divided BID, titrated to trough levels (typically 100-300 ng/mL depending on regimen and post-transplant interval); ophthalmic Restasis 0.05% one drop BID
Treatment 70 mg PO once weekly (or 10 mg daily); prevention 35 mg weekly (or 5 mg daily); always taken first thing in the morning with a full glass of water, remaining upright for 30 minutes
Treatment: 75 mg PO BID × 5 days (adult); pediatric weight-based; prophylaxis: 75 mg PO once daily × 7-10 days
Trials use 25 mg or 50 mg PO daily
Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice
Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment
Victoza: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000181-QINU`"' · Saxenda: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000182-QINU`"'
Volume and concentration titrated to clinical status; symptomatic hyponatremia: 3% NaCl 100-150 mL bolus, reassess
Volume titrated to clinical status; typical adult bolus 500-1000 mL, then reassess
Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d
Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w
Week 1: 1 tablet (8/90 mg) PO morning; week 2: 1 tablet AM + 1 PM; week 3: 2 AM + 1 PM; week 4 onward: 2 AM + 2 PM (32 mg naltrexone / 360 mg bupropion/d)
Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed.
XR 37.5 mg PO once daily for 4-7 days, then 75 mg/day; titrate by 75 mg every ≥4 days to clinical effect. IR 25-37.5 mg BID-TID
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses
Search
preparations:
100 mg tabs (1)
fda max:
(Click arrow to add another value)
None
·
Indication-specific
·
40 mg/d
·
10 mg/d
·
20 mg/d
·
80 mg/d
·
10 mg/d (adults)
· 100 mg/d ·
4 g/d
·
400 mg/d
·
40 mg/d typical; up to 240 mg/d for Zollinger-Ellison
·
5 mg/d
·
50 mg/d
·
600 mg/d
·
No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals
·
No fixed maximum; titrated to TSH target
·
TID per eye
·
Titrated to glucose; no fixed ceiling
·
Titrated to glucose; no fixed maximum
·
'''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60
Other values:
'''4.5 mg/kg (without epinephrine), 7 mg/kg (with epinephrine)''' for infiltration; serum level monitoring required for prolonged IV antiarrhythmic use
0.5 mg/d
0.8 mg/d (rarely needed)
1 capsule BID (40 mg DXM / 20 mg quinidine per day)
1 drop per eye q8-12h
1 drop/eye/day (more frequent dosing reduces efficacy)
1 g/d (oral); 6 g/d (IV)
1 mg/d
1 mg/d typical Rx; higher in specific indications
1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors
1.8 mg/day SC (Victoza, T2DM)'"`UNIQ--ref-00000185-QINU`"' · 3.0 mg/day SC (Saxenda, obesity)'"`UNIQ--ref-00000186-QINU`"'
10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID
10 mg per 24 h
10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors)
10 mg/day (IR); 12.5 mg/day (CR)
10 mg/day (anxiety, oral)
10 mg/kg q2w
10 µg twice daily (Byetta)'"`UNIQ--ref-000000E7-QINU`"' · 2 mg once weekly (Bydureon BCise)'"`UNIQ--ref-000000E8-QINU`"'
100 mcg/d typical
100 mg/d (ED); 20 mg TID (PAH)
100 mg/d (rarely used)
100 mg/day (adult)
100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower)
100 mg/day (vertigo)
100-200 mg/day depending on indication
1000 mg/d (osteoarthritis); 1200 mg/d (rheumatoid arthritis)
12 inhalations/d (rescue); higher for severe exacerbation under monitoring
12 puffs MDI/d typical; nebulized 2000 mcg/d
120 mg/d (ER); IR not for chronic hypertension
120 mg/day (IV/IM); 40 mg/day (oral); '''5-day maximum total combined therapy''' to mitigate the GI bleeding, AKI, and platelet dysfunction risks
1200 mg/day (adult seizures); 1600 mg/day (bipolar mania)
140 mg/month
1400 mg q4w
15 mg/day (oral); 30 mg IV once daily (Anjeso)
15 mg/wk SC'"`UNIQ--ref-000002FE-QINU`"''"`UNIQ--ref-000002FF-QINU`"'
150 mg/d
150 mg/d (treatment)
150 mg/day (oral); use lowest effective dose for shortest duration per FDA NSAID class guidance
150 mg/day; therapeutic plasma-level monitoring recommended (target 50-150 ng/mL window)
1500 mg/day (Rx); 660 mg/24h (OTC, without provider direction)
16 mg/d (8 mg/d OTC)
16 mg/d (IR); 8 mg/d (XL)
16 mg/day (schizophrenia, adult); 6 mg/day (bipolar maintenance, autism irritability)
160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications
160 mg/d (rarely tolerated due to anticholinergic effects)
1600 mg/day (theoretical seizure dosing); practical use 400 mg/day for seizures, 100-200 mg/day for migraine prophylaxis
18 mg olanzapine / 75 mg fluoxetine per day
180 mg/d (adults)
195 units/treatment for chronic migraine; max varies by problem
2 g/d (Niaspan); higher off-label use historical
2 g/d typical
2 g/day (seizures); typically much lower for essential tremor
2 mg/wk SC (Ozempic)'"`UNIQ--ref-0000024B-QINU`"' · 2.4 mg/wk SC (Wegovy)'"`UNIQ--ref-0000024C-QINU`"' · 14 mg PO daily (Rybelsus)'"`UNIQ--ref-0000024D-QINU`"'
2 sprays/nostril BID
2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache
2 tablets/day (dextromethorphan 90 mg / bupropion 210 mg)
2.4 g/d
2.4 mg/day (HTN, IR); 0.4 mg/day (ADHD, Kapvay)
20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH)
20 mg/d (hypertension); 10 mg/d (other indications typical)
20 mg/day (IR); 28 mg/day (XR)
20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment
20 mg/day (oral)
20 mg/day (seizures); commonly limited to 4 mg/day for anxiety in current practice
200 mg/d
200 mg/d (100 mg/d if on CYP3A4 inhibitors)
200 mg/d typical practical ceiling
200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra)
200 mg/day (typical adult oral)
2000 mg/d
225 mg/day outpatient (XR); 375 mg/day inpatient (IR divided TID); 75 mg/day in moderate hepatic impairment
23 mg/day
24 mg/day (Parkinson disease); 4 mg/day (restless legs syndrome)
24/6 mg/d (most labels)
240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster
240 mg/d (mononitrate ER); 160 mg/d (dinitrate)
240 mg/day
2400 mg/day (adult)
2400 mg/day (oral); 300 mg total per IV bolus dosing series
25 mg/d
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
250 mg/d
2550 mg/d (IR); 2000 mg/d (ER)
28/10 mg/d
290 mcg/d
3 g/d (zoster)
3 g/d typical; higher in severe infections under specialist guidance
30 mg/24 hours
30 mg/d (XL) typical
30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d
30 mg/d for short-term use
30 mg/day (IR or ER)
30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct)
300 mg/d
300 mg/d typical practical limit (toxicity rises sharply above)
300 mg/day (IR or CR)
300 mg/day (depression, hospitalized); 150 mg/day outpatient; 6 mg/day for insomnia
300 mg/day (historical hospitalized inpatient depression); 150 mg/day outpatient typical ceiling
300 mg/day (oral)
300 mg/quarter
3000 mg/day
32 mg naltrexone / 360 mg bupropion per day
32 mg/day adult; weight-based pediatric ceiling
320 mg/d (hypertension); 320 mg/d (HF)
3200 mg/day (Rx); 1200 mg/day (OTC, without provider direction)
34 mg/d
35.6 mg/d
36 mg/day in three divided doses; single dose maximum 16 mg
360 mg/day
3600 mg/day; off-label doses higher are common but bioavailability saturates well below this
37.5 mg/d
4 L per procedure (standard-volume products)
4 g/d (rarely tolerated due to GI effects)
4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use
4 g/d typical
4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct)
4% topical; limit duration of use
4.5 mg/day (Parkinson disease); 0.5 mg/day (restless legs syndrome)
4.5 mg/wk SC'"`UNIQ--ref-00000055-QINU`"'
4.8 g/d (IV severe infection)
40 mg every week (selected indications); otherwise 40 mg every other week
40 mg/d (IR; doses >15 mg given as divided BID); 20 mg/d (XL)
40 mg/d (rarely needed; 40 mg restricted to patients not at goal on 20 mg)
40 mg/d standard; 80 mg/d restricted to patients tolerating 80 mg for ≥12 months without myopathy (post-SEARCH 2011 FDA restriction)
40 mg/d typical; up to 360 mg/d for Zollinger-Ellison
40 mg/day (oral, anxiety)
400 mg/d (acute primary aldosteronism diagnosis); 100-200 mg/d typical chronic
400 mg/d (pediatric); 600 mg/d (adult)
400 mg/d (rarely used)
400 mg/d typical maintenance; weight-adjusted ceiling per ophthalmology guidance
400 mg/day (IR, adult); 300 mg/day (ER); 300 mg/day in elderly >75 years
400 mg/day (bipolar monotherapy); 700 mg/day (epilepsy with enzyme-inducing comedication)
400 mg/day for chronic indications; higher for short-term acute pain
400 mg/day outpatient; 600 mg/day inpatient
400 mg/day theoretical; in practice rarely exceeds 200 mg/day
4000 mg/day (analgesic)
42 mg/d
420 mg/month
45 mg/d
45 mg/day
450 mg/day; doses above this raise seizure risk steeply
5 mg/d (adults)
50 g/week (cream/ointment); 2-week continuous limit; 4-week maximum cumulative
50 mg BID in heart failure (or once-daily equivalent CR); 25 mg BID in hypertension
50 mg/d (hypertension); up to 200 mg/d (edema)
50 mg/d × 14 d
50 mg/day (IR); 62.5 mg/day (CR); 60 mg/day (OCD)
50 mg/day (no efficacy benefit shown for higher doses despite the 100 mg strength being available)
500 mg/d (typical regimen); single 2 g for Zmax; 2 g for select STIs
6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine)
6 capsules/d (300 mg butalbital, 1950 mg aspirin, 240 mg caffeine)
6 mg/d (psychosis/mania); 3 mg/d (depression adjunct)
60 mg/d typical
60 mg/day
60 mg/day (oral, hypertension); 0.5% BID (ophthalmic)
60 mg/kg/d (typically up to 3000 mg/d)
600 mg/d typical practical ceiling in heart failure
600 mg/day (seizures); 450 mg/day (fibromyalgia and neuropathic pain)
640 mg/d (HTN); 240 mg/d (migraine)
675 mg/quarter
7 mg/day in children and adolescents; weight-based ceiling (~0.12 mg/kg/day) applies in smaller patients
70 mg/day
70 mg/week treatment; 40 mg/d for 6 months in Paget's
75 mg per dose; one dose per 24 hours (acute); one dose every other day (preventive)
75 mg/d maintenance (loading doses are single events)
750 mg/d
8 g/day (oral, short-term load); 6 g/day (chronic)
8 mg/d
8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label
80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions)
80 mg/day oral (higher off-label)
800 mg/d
800 mg/d (rarely needed)
800 mg/d (severe invasive disease)
800 mg/day
84 mg per session
9 g/night
90 mg BID (acute year); 60 mg BID (chronic post-MI)
Acetaminophen 4 g/d absolute (3 g/d conservative); oxycodone titrated to effect
Acetaminophen 4 g/d absolute; codeine 240-360 mg/d typical practical limit
Aspirin GI/bleeding-limited; oxycodone titrated to effect
BID topical; once daily nail lacquer
Formulation-dependent
Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen)
Formulation-specific; ~4.8 g/d typical maximum oral
ICS 880 mcg/d (asthma); intranasal 200 mcg/d
ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard
IV peripheral 10 mEq/h (40 mEq/L); IV central 20 mEq/h with cardiac monitoring; PO single doses generally ≤40 mEq
IV: monitored by levels (trough <1 mg/L for extended-interval; <2 mg/L for traditional)
Indication-dependent; 200-400 mg/d oral typical
Indication-specific; ACLS no fixed cumulative ceiling
Indication-specific; HE may require high-volume dosing
Indication-specific; bowel prep regimens reach 4 L cumulative
Indication-specific; high-dose IV regimens for encephalitis or disseminated disease
Indication-specific; lowest effective dose for shortest duration is the WHI-era standard
Indication-specific; renal clearance limits tolerable cumulative dosing
Indication-specific; titrated to effect
Intranasal 200 mcg/d (adults); inhaled 880 mcg/d
Limit to 48 hours of use to avoid hemolysis and methemoglobinemia
Limit topical to 10-day courses to reduce resistance pressure
N/A (never approved)
N/A (no current medical indication)
No fixed maximum; cumulative-dose toxicity drives all chronic decisions
No fixed maximum; titrated to INR target
No fixed maximum; titrated to clinical endpoints
No fixed maximum; titrated to pH and bicarbonate level; chronic high oral doses cause metabolic alkalosis and volume overload
No fixed maximum; titrated; sodium correction rate in chronic hyponatremia must not exceed 8-10 mEq/L per 24 hours to avoid osmotic demyelination
No strict ceiling for water-soluble vitamin; UL not set
No strict ceiling; water-soluble vitamin, low toxicity
No strict; Institute of Medicine UL 4,000 IU/d in adults for chronic use
Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing
Not formally established (dietary supplement); doses above ~3-5 mg show no additional efficacy but increase next-day sedation risk
Not strictly fixed; long-term Upper Limit ~4,000 IU/d in adults (Institute of Medicine)
Not yet approved
Once daily (Pataday 0.7%); BID (other ophthalmic)
One dose per day
One drop per eye per day
Oral maintenance 400 mg/d typical; higher in refractory cases
Per formulation
Rheumatologic ~25 mg/week; oncology indication-specific
Single 200-400 mcg/kg per dose for systemic indications
Single 60-hour course
Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided
Titrated to glucose
Titrated; risk of hypercalcemia is the limiting factor
Topical: BID; troche: 5×/day
Topical: nightly; oral APL: 45 mg/m²/d
Topical: nightly; systemic: regimen-specific
Topical: per formulation; oral supplement age-dependent
Topical: regimen-specific; oral: 400 mg/d in remaining specialty indications
Transplant: regimen-specific
UL 1000 mg (~1500 IU natural)/d in adults; routinely exceeded in older AREDS-1 trials
UL 2000 mg/d in adults
Withdrawn 2024
XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"'
~10 mg/d typical
~1500 mg/d (oral); 1200 mg/d (IV)
~200 mg elemental iron/d typical practical limit
~200 mg/d for most indications; higher doses for severe infections
~2500 mg elemental/d combined diet + supplements (chronic; UL)
~4 g/d (severe systemic infection)
~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster
~480 mg/d (oral); IV per protocol
~500 mg/d typical
Search
routes:
Oral (1)
onset:
Effects accumulate over weeks; assess at 8 weeks (1)
duration:
Continuous daily dosing (1)
halflife:
~11 h (1)
bioavailability:
~33% (1)
pregnancy:
Not indicated; pregnancy effects unknown (1)
legal:
Rx-only in US (REMS program) (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.
Search
Search
Drilldown: Medicines
Add topic
& starting dose:
100 mg at bedtime daily 
generic:
uses: (Click arrow to add another value)